Prometheus Biosciences announced that it intends to offer and sell, subject to market and other conditions, $250M of shares of its common stock in an underwritten public offering. Prometheus intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and short-term investments to fund the development of PRA023, PRA052 and its other research and development programs, and for working capital and general corporate purposes. Goldman Sachs & Co., SVB Securities, Jefferies, and Guggenheim Securities are acting as joint bookrunning managers for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RXDX:
- Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
- Prometheus Biosciences Shares Tripled Today after Positive Drug Results
- Prometheus price target raised to $185 from $75 at Guggenheim
- Prometheus price target raised to $114 from $67 at Piper Sandler
- Stifel ‘thoroughly impressed’ with Prometheus’ data in UC and CD